Nanotechnology-enhanced gene therapy for hearing loss

Area of Science:

• Otolaryngology
• Biotechnology
• Nanomedicine

Background:

• Hearing loss affects millions globally, with current treatments providing only functional restoration.
• Existing interventions like hearing aids and cochlear implants do not address the underlying molecular causes of hearing impairment.
• Gene therapy presents a potential solution for restoring hearing by correcting genetic defects, but requires effective delivery systems.

Purpose of the Study:

• To review the integration of nanotechnology with gene therapy for treating hearing loss.
• To explore nanoparticle-based delivery systems for inner ear gene therapy.
• To discuss biological mechanisms, technological innovations, and clinical challenges in nanotechnology-enhanced gene therapy for hearing loss.

Main Methods:

• Review of recent advancements and preclinical studies in nanotechnology and gene therapy for hearing loss.
• Analysis of nanoparticle design, targeting strategies, and delivery systems for inner ear applications.
• Examination of biological mechanisms of hearing loss and gene therapy approaches.

Main Results:

• Nanoparticles serve as non-viral carriers for protecting genetic material and targeting cochlear cells.
• Nanotechnology enables minimally invasive delivery, promoting cellular regeneration.
• Preclinical studies demonstrate the potential of nanotechnology-enhanced gene therapy.

Conclusions:

• Nanotechnology-enhanced gene therapy holds significant potential to revolutionize hearing loss treatment.
• Addressing the root causes of hearing loss through targeted gene delivery is achievable.
• Overcoming barriers to clinical translation is crucial for realizing the therapeutic benefits.